Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Schizophrenia

Free Subscription Articles published in Mol Psychiatry Retrieve available abstracts of 157 articles: HTML format

Single Articles

October 2025
1. WALTHER S, Maderthaner L, Chapellier V, von Kanel S, et al
   Gesture deficits in psychosis and the combination of group psychotherapy and transcranial magnetic stimulation: A randomized clinical trial.
   Mol Psychiatry. 2025 Oct 8. doi: 10.1038/s41380-025-03303.
   PubMed     Abstract available
   
   
   
2. MARTINEZ-SADURNI L, Barrera-Conde M, Robledo P, Veza-Estevez E, et al
   Differential effect of cannabis use and antipsychotic medication on extracellular free-water in the brain of individuals with early psychosis and controls.
   Mol Psychiatry. 2025 Oct 7. doi: 10.1038/s41380-025-03287.
   PubMed     Abstract available
   
   
   
3. CARR R, Cannon A, Finelli V, Bukala B, et al
   Non-Clozapine interventions in treatment-resistant schizophrenia: a systematic review and meta-analysis.
   Mol Psychiatry. 2025 Oct 3. doi: 10.1038/s41380-025-03255.
   PubMed     Abstract available
   
   
   
4. OHTANI H, Ichikawa R, Mori K, Kato T, et al
   Single-molecule DNA analysis implicates brain mitochondria pathology in bipolar disorder.
   Mol Psychiatry. 2025;30:4764-4775.
   PubMed     Abstract available
   
   
   
5. DARDANI C, Robinson JW, Jones HJ, Rai D, et al
   Immunological drivers and potential novel drug targets for major psychiatric, neurodevelopmental, and neurodegenerative conditions.
   Mol Psychiatry. 2025;30:4487-4496.
   PubMed     Abstract available
   
   
   September 2025
6. SINANAJ L, Pallis K, Dehkordi AF, Huguelet P, et al
   Mapping symptom-general and symptom-specific targets for transcranial magnetic stimulation in schizophrenia: an electric-field modeling meta-analysis.
   Mol Psychiatry. 2025 Sep 22. doi: 10.1038/s41380-025-03238.
   PubMed     Abstract available
   
   
   
7. SU X, Zhang H, Hong Y, Yang Q, et al
   Mutations of schizophrenia risk gene SETD1A dysregulate synaptic function in human neurons.
   Mol Psychiatry. 2025 Sep 17. doi: 10.1038/s41380-025-03246.
   PubMed     Abstract available
   
   
   
8. BOJESEN KB, Lemvigh CK, Sigvard AK, Vestergaard MB, et al
   Cerebral glutamate levels over two years in initially antipsychotic-naive first-episode patients with psychosis are related to clinical symptoms and cognition.
   Mol Psychiatry. 2025 Sep 15. doi: 10.1038/s41380-025-03234.
   PubMed     Abstract available
   
   
   
9. BOJESEN KB, Ambrosen KS, Sigvard AK, Nielsen MO, et al
   Interrelations between dopaminergic-, gabaergic- and glutamatergic neurotransmitters in antipsychotic-naive psychosis patients and the association to initial treatment response.
   Mol Psychiatry. 2025 Sep 12. doi: 10.1038/s41380-025-03229.
   PubMed     Abstract available
   
   
   
10. LUKOW PB, Schubert JJ, Severino M, Knight SR, et al
    GABA(A) receptor availability in clinical high-risk and first-episode psychosis: a [(11)C]Ro15-4513 positron emission tomography study.
    Mol Psychiatry. 2025 Sep 6. doi: 10.1038/s41380-025-03204.
    PubMed     Abstract available
    
    
    
11. VANO LJ, McCutcheon RA, Sedlacik J, Rutigliano G, et al
    The role of low subcortical iron, white matter myelin, and oligodendrocytes in schizophrenia: a quantitative susceptibility mapping and diffusion tensor imaging study.
    Mol Psychiatry. 2025 Sep 5. doi: 10.1038/s41380-025-03195.
    PubMed     Abstract available
    
    
    
12. AHIRWAR LK, Blackburn SL, McBride DW, T PK, et al
    Reviewing vascular influences on neuronal migration, cortical development, and neurodevelopmental disorders: focus on autism, ADHD and schizophrenia.
    Mol Psychiatry. 2025 Sep 2. doi: 10.1038/s41380-025-03200.
    PubMed     Abstract available
    
    
    
13. LU Z, Guo J, Sun J, Sun Y, et al
    The event-related potential components across psychiatric disorders: a systematic review and network meta-analysis.
    Mol Psychiatry. 2025;30:4422-4431.
    PubMed     Abstract available
    
    
    
14. SOLOMON P, Kaurani L, Budde M, Guine JB, et al
    Integrative analysis of miRNA expression profiles reveals distinct and common molecular mechanisms underlying broad diagnostic groups of severe mental disorders.
    Mol Psychiatry. 2025;30:4364-4383.
    PubMed     Abstract available
    
    
    
15. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
    Exploring the implications of case selection methods for psychiatric molecular genetic studies.
    Mol Psychiatry. 2025;30:4334-4342.
    PubMed     Abstract available
    
    
    
16. STEIN F, Gudjons AM, Brosch K, Keunecke LM, et al
    Transdiagnostic types of formal thought disorder and their association with gray matter brain structure: a model-based cluster analytic approach.
    Mol Psychiatry. 2025;30:4286-4295.
    PubMed     Abstract available
    
    
    
17. HOLTER KM, Klausner MG, Hite MH, Moriarty CT, et al
    17beta-estradiol status alters NMDAR function and antipsychotic-like activity in female rats.
    Mol Psychiatry. 2025;30:4161-4175.
    PubMed     Abstract available
    
    
    August 2025
18. WOODS RM, Potter HG, Kowash HM, McEwan F, et al
    Developmental modulation of schizophrenia risk gene methylation in offspring exhibiting cognitive deficits following maternal immune activation.
    Mol Psychiatry. 2025 Aug 29. doi: 10.1038/s41380-025-03147.
    PubMed     Abstract available
    
    
    
19. FAN YS, Xu Y, Hettwer MD, Yang P, et al
    Neurodevelopmentally rooted epicenters in schizophrenia: sensorimotor-association spatial axis of cortical thickness alterations.
    Mol Psychiatry. 2025 Aug 28. doi: 10.1038/s41380-025-03193.
    PubMed     Abstract available
    
    
    
20. UNZUETA-LARRINAGA P, Cuesta-Vega E, Barrena-Barbadillo R, Olabarrieta E, et al
    Extracellular matrix dysfunction and synaptic alterations in schizophrenia.
    Mol Psychiatry. 2025 Aug 27. doi: 10.1038/s41380-025-03154.
    PubMed     Abstract available
    
    
    
21. CUI Y, Sun J, Zhang B, Guo T, et al
    Efficacy and safety of transcutaneous auricular vagus nerve stimulation for patients with treatment-resistant schizophrenia with predominantly negative symptoms: a randomized clinical trial and efficacy sensitivity biomarkers.
    Mol Psychiatry. 2025 Aug 26. doi: 10.1038/s41380-025-03132.
    PubMed     Abstract available
    
    
    
22. WAKUDA T, Yokokura M, Magata Y, Suzuki C, et al
    alpha7 nicotinic acetylcholine receptor, activated glia, and cognitive impairment in schizophrenia: a dual-tracer PET study.
    Mol Psychiatry. 2025 Aug 19. doi: 10.1038/s41380-025-03162.
    PubMed     Abstract available
    
    
    
23. VAZIRI N, Shutt TE, Karim W, Raedler TJ, et al
    Examination of mitochondria- and inflammasome-mediated mechanisms of clozapine-induced myocarditis using patient-derived iPSC cardiomyocytes.
    Mol Psychiatry. 2025;30:3491-3501.
    PubMed     Abstract available
    
    
    July 2025
24. SALAMONE PC, Enmalm A, Kaldewaij R, Aman M, et al
    Altered processing of self-produced sensations in psychosis at cortical and spinal levels.
    Mol Psychiatry. 2025 Jul 25. doi: 10.1038/s41380-025-03130.
    PubMed     Abstract available
    
    
    
25. GARCIA-RIZO C, Bitanihirwe BKY
    Epiphenomena in psychosis: how perinatal stressful events shape long-term outcomes.
    Mol Psychiatry. 2025 Jul 11. doi: 10.1038/s41380-025-03096.
    PubMed     Abstract available
    
    
    
26. LI H, Zhao Z, Jiang S, Wu H, et al
    Brain circuits that regulate social behavior.
    Mol Psychiatry. 2025;30:3240-3256.
    PubMed     Abstract available
    
    
    
27. HAGENBEEK FA, Pool R, Van Asselt AJ, Ehli EA, et al
    Intergenerational transmission of complex traits and the offspring methylome.
    Mol Psychiatry. 2025;30:3338-3347.
    PubMed     Abstract available
    
    
    
28. HERRERO F, Heeb C, Meier M, Lin HY, et al
    Recapitulation and reversal of neuropsychiatric phenotypes in a mouse model of human endogenous retrovirus type W expression.
    Mol Psychiatry. 2025;30:3325-3337.
    PubMed     Abstract available
    
    
    
29. KIM H, Jung JH, Han K, Jeon HJ, et al
    Risk of suicide and all-cause death in patients with mental disorders: a nationwide cohort study.
    Mol Psychiatry. 2025;30:2831-2839.
    PubMed     Abstract available
    
    
    
30. LUYKX JJ, Corbeil O, Karkkainen O, Tanskanen A, et al
    Long term safety of ADHD medication in patients with schizophrenia spectrum disorders.
    Mol Psychiatry. 2025 Jul 1. doi: 10.1038/s41380-025-03080.
    PubMed     Abstract available
    
    
    June 2025
31. SZESZKO PR, Kowalchyk M, Chu KW, Aladin S, et al
    Investigation of brain white matter and social cognition in schizophrenia and schizotypal personality disorder using neurite orientation dispersion and density imaging.
    Mol Psychiatry. 2025 Jun 7. doi: 10.1038/s41380-025-03074.
    PubMed     Abstract available
    
    
    
32. SUI YV, Bertisch H, Goff DC, Samsonov A, et al
    Quantitative magnetization transfer and g-ratio imaging of white matter myelin in early psychotic spectrum disorders.
    Mol Psychiatry. 2025;30:2739-2747.
    PubMed     Abstract available
    
    
    May 2025
33. VILLARIN JM, Kellendonk C
    An ace in the hole? Opportunities and limits of using mice to understand schizophrenia neurobiology.
    Mol Psychiatry. 2025 May 22. doi: 10.1038/s41380-025-03060.
    PubMed     Abstract available
    
    
    
34. BYUN AJS, Lane E, Langholm C, Flathers M, et al
    Towards clinical subtypes in schizophrenia: integrating cognitive, functional, and digital phenotyping assessments.
    Mol Psychiatry. 2025 May 20. doi: 10.1038/s41380-025-03054.
    PubMed     Abstract available
    
    
    
35. SAINT-GEORGES Z, MacDonald J, Al-Khalili R, Hamati R, et al
    Cholinergic system in schizophrenia: A systematic review and meta-analysis.
    Mol Psychiatry. 2025 May 20. doi: 10.1038/s41380-025-03023.
    PubMed     Abstract available
    
    
    
36. HUA L, Zeng X, Zhang K, Zhao Z, et al
    Reduced glymphatic clearance in early psychosis.
    Mol Psychiatry. 2025 May 19. doi: 10.1038/s41380-025-03058.
    PubMed     Abstract available
    
    
    
37. BANERJEE A, Wang HY, Borgmann-Winter KE, MacDonald ML, et al
    Editorial Expression of Concern: Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia.
    Mol Psychiatry. 2025 May 13. doi: 10.1038/s41380-025-03050.
    PubMed    
    
    
    
38. FARHANGDOOST N, Liao C, Liu Y, Rochefort D, et al
    Transcriptomic and epigenomic consequences of heterozygous loss-of-function mutations in AKAP11, a shared risk gene for bipolar disorder and schizophrenia.
    Mol Psychiatry. 2025 May 2. doi: 10.1038/s41380-025-03040.
    PubMed     Abstract available
    
    
    
39. HATANO M, Nakajima W, Tani H, Uchida H, et al
    Characterization of patients with major psychiatric disorders with AMPA receptor positron emission tomography.
    Mol Psychiatry. 2025;30:1780-1790.
    PubMed     Abstract available
    
    
    April 2025
40. WANG HY, MacDonald ML, Borgmann-Winter KE, Banerjee A, et al
    Retraction Note: mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia.
    Mol Psychiatry. 2025 Apr 17. doi: 10.1038/s41380-025-02986.
    PubMed    
    
    
    
41. HATZIPANAYIOTI A, Walther S, Gangl N, Conring F, et al
    Aberrant personal space is associated with paranoia, altered stress regulation, and unfavourable outcomes at 6 months' follow-up in schizophrenia.
    Mol Psychiatry. 2025 Apr 9. doi: 10.1038/s41380-025-02999.
    PubMed     Abstract available
    
    
    
42. NUCIFORA LG, Ishizuka K, El Demerdash N, Lee BJ, et al
    Protein aggregation identified in olfactory neuronal cells is associated with cognitive impairments in a subset of living schizophrenia patients.
    Mol Psychiatry. 2025 Apr 3. doi: 10.1038/s41380-025-02956.
    PubMed     Abstract available
    
    
    
43. XIE Y, Fu J, Liu L, Wang X, et al
    Genetic and neural mechanisms shared by schizophrenia and depression.
    Mol Psychiatry. 2025 Apr 3. doi: 10.1038/s41380-025-02975.
    PubMed     Abstract available
    
    
    
44. YAO S, Kendrick KM
    How does oxytocin modulate human behavior?
    Mol Psychiatry. 2025;30:1639-1651.
    PubMed     Abstract available
    
    
    
45. MIURA K, Yoshida M, Morita K, Fujimoto M, et al
    Gaze behaviors during free viewing revealed differences in visual salience processing across four major psychiatric disorders: a mega-analysis study of 1012 individuals.
    Mol Psychiatry. 2025;30:1594-1600.
    PubMed     Abstract available
    
    
    
46. ITAHASHI T, Yamashita A, Takahara Y, Yahata N, et al
    Generalizable and transportable resting-state neural signatures characterized by functional networks, neurotransmitters, and clinical symptoms in autism.
    Mol Psychiatry. 2025;30:1466-1478.
    PubMed     Abstract available
    
    
    March 2025
47. GIACOMEL A, Martins D, Nordio G, Easmin R, et al
    Correction: Investigating dopaminergic abnormalities in schizophrenia and first-episode psychosis with normative modelling and multisite molecular neuroimaging.
    Mol Psychiatry. 2025 Mar 31. doi: 10.1038/s41380-025-02987.
    PubMed    
    
    
    
48. RABALLO A, Poletti M, Preti A
    Increasing conceptual clarity and confounders identification: a pragmatic way to enhance prognostic precision in ENIGMA clinical high risk for psychosis (CHR-P).
    Mol Psychiatry. 2025 Mar 17. doi: 10.1038/s41380-025-02948.
    PubMed    
    
    
    
49. FENG YA, Chen WJ, Lin MC, Hsu JS, et al
    Paternal age, de novo mutation, and age at onset among co-affected schizophrenia sib-pairs: whole-genome sequencing in multiplex families.
    Mol Psychiatry. 2025 Mar 5. doi: 10.1038/s41380-025-02942.
    PubMed     Abstract available
    
    
    
50. ZHAO Q, Wei X, Yu W, Li X, et al
    Morphological alterations of the thymus gland in individuals with schizophrenia.
    Mol Psychiatry. 2025 Mar 4. doi: 10.1038/s41380-025-02946.
    PubMed     Abstract available
    
    
    
51. ARBABI K, Newton DF, Oh H, Davie MC, et al
    Transcriptomic pathology of neocortical microcircuit cell types across psychiatric disorders.
    Mol Psychiatry. 2025;30:1057-1068.
    PubMed     Abstract available
    
    
    
52. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
    The number of episodes of major psychiatric and substance use disorders as an index of genetic risk and genetic heterogeneity.
    Mol Psychiatry. 2025;30:968-975.
    PubMed     Abstract available
    
    
    February 2025
53. GIACOMEL A, Martins D, Nordio G, Easmin R, et al
    Investigating dopaminergic abnormalities in schizophrenia and first-episode psychosis with normative modelling and multisite molecular neuroimaging.
    Mol Psychiatry. 2025 Feb 28. doi: 10.1038/s41380-025-02938.
    PubMed     Abstract available
    
    
    
54. KEIHANI A, Donati FL, Janssen SA, Huston CA, et al
    Multimodal evidence of mediodorsal thalamus-prefrontal circuit dysfunctions in clinical high-risk for psychosis: findings from a combined 7T fMRI, MRSI and sleep Hd-EEG study.
    Mol Psychiatry. 2025 Feb 15. doi: 10.1038/s41380-025-02924.
    PubMed     Abstract available
    
    
    
55. MINICHINO A, Davies C, Karpenko O, Christodoulou N, et al
    Preventing psychosis in people at clinical high risk: an updated meta-analysis by the World Psychiatric Association Preventive Psychiatry section.
    Mol Psychiatry. 2025 Feb 14. doi: 10.1038/s41380-025-02902.
    PubMed     Abstract available
    
    
    
56. DI RE J, Marini M, Hussain SI, Singh AK, et al
    betaIV spectrin abundancy, cellular distribution and sensitivity to AKT/GSK3 regulation in schizophrenia.
    Mol Psychiatry. 2025 Feb 7. doi: 10.1038/s41380-025-02917.
    PubMed     Abstract available
    
    
    
57. VINKE LN, Avanaki M, Jeffrey C, Harikumar A, et al
    Neural correlates of personal space regulation in psychosis: role of the inferior parietal cortex.
    Mol Psychiatry. 2025 Feb 3. doi: 10.1038/s41380-025-02906.
    PubMed     Abstract available
    
    
    January 2025
58. CHESTNYKH D, Muhle C, Schumacher F, Kalinichenko LS, et al
    Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment strategy for schizophrenia.
    Mol Psychiatry. 2025 Jan 17. doi: 10.1038/s41380-025-02893.
    PubMed     Abstract available
    
    
    
59. MARQUES D, Vaziri N, Greenway SC, Bousman C, et al
    DNA methylation and histone modifications associated with antipsychotic treatment: a systematic review.
    Mol Psychiatry. 2025;30:296-309.
    PubMed     Abstract available
    
    
    
60. CIULKINYTE A, Mountford HS, Fontanillas P, Bates TC, et al
    Genetic neurodevelopmental clustering and dyslexia.
    Mol Psychiatry. 2025;30:140-150.
    PubMed     Abstract available
    
    
    
61. LI X, Xue C, Zhu Z, Yu X, et al
    Application of GWAS summary data and drug-induced gene expression profiles of neural progenitor cells in psychiatric drug prioritization analysis.
    Mol Psychiatry. 2025;30:111-121.
    PubMed     Abstract available
    
    
    December 2024
62. EISENBERG DP, Blackman RK, Tietcheu MG, Kohn PD, et al
    Genetic risk for treatment resistant schizophrenia and corresponding variation in dopamine synthesis capacity and D(2/3) receptor availability in healthy individuals.
    Mol Psychiatry. 2024 Dec 27. doi: 10.1038/s41380-024-02873.
    PubMed     Abstract available
    
    
    
63. XIA C, Alliey-Rodriguez N, Tamminga CA, Keshavan MS, et al
    Genetic analysis of psychosis Biotypes: shared Ancestry-adjusted polygenic risk and unique genomic associations.
    Mol Psychiatry. 2024 Dec 21. doi: 10.1038/s41380-024-02876.
    PubMed     Abstract available
    
    
    
64. SOLMI M, Fornaro M, Caiolo S, Lussignoli M, et al
    Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis.
    Mol Psychiatry. 2024 Dec 18. doi: 10.1038/s41380-024-02733.
    PubMed     Abstract available
    
    
    
65. COHEN LS, Arakelian M, Church TR, Dunk MM, et al
    The phenomenology of postpartum psychosis: preliminary findings from the Massachusetts General Hospital Postpartum Psychosis Project.
    Mol Psychiatry. 2024 Dec 6. doi: 10.1038/s41380-024-02856.
    PubMed     Abstract available
    
    
    
66. BERNSTEIN HG, Nussbaumer M, Vasilevska V, Dobrowolny H, et al
    Glial cell deficits are a key feature of schizophrenia: implications for neuronal circuit maintenance and histological differentiation from classical neurodegeneration.
    Mol Psychiatry. 2024 Dec 5. doi: 10.1038/s41380-024-02861.
    PubMed     Abstract available
    
    
    
67. SCHALBROECK R, van Hooijdonk CFM, Bos DPA, Booij J, et al
    Chronic social stressors and striatal dopamine functioning in humans: A systematic review of SPECT and PET studies.
    Mol Psychiatry. 2024;29:3841-3856.
    PubMed     Abstract available
    
    
    November 2024
68. SABE M, Sulstarova A, Glangetas A, De Pieri M, et al
    Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.
    Mol Psychiatry. 2024 Nov 27. doi: 10.1038/s41380-024-02800.
    PubMed     Abstract available
    
    
    
69. NELSON EA, Kraguljac NV, Bashir A, Cofield SS, et al
    A longitudinal study of hippocampal subfield volumes and hippocampal glutamate levels in antipsychotic-naive first episode psychosis patients.
    Mol Psychiatry. 2024 Nov 23. doi: 10.1038/s41380-024-02812.
    PubMed     Abstract available
    
    
    
70. WEIDENAUER A, Dajic I, Praschak-Rieder N, Willeit M, et al
    The dopaminergic basis of negative symptoms in schizophrenia: an addendum.
    Mol Psychiatry. 2024 Nov 20. doi: 10.1038/s41380-024-02828.
    PubMed    
    
    
    
71. CHEN L, Huai C, Song C, Wu S, et al
    Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction.
    Mol Psychiatry. 2024 Nov 19. doi: 10.1038/s41380-024-02841.
    PubMed     Abstract available
    
    
    
72. WALKER A, Karlsson R, Szatkiewicz JP, Thornton LM, et al
    Genome-wide copy number variation association study in anorexia nervosa.
    Mol Psychiatry. 2024 Nov 12. doi: 10.1038/s41380-024-02811.
    PubMed     Abstract available
    
    
    
73. NISHA AJI K, Lalang N, Ramos-Jimenez C, Rahimian R, et al
    Evidence of altered monoamine oxidase B, an astroglia marker, in early psychosis and high-risk state.
    Mol Psychiatry. 2024 Nov 7. doi: 10.1038/s41380-024-02816.
    PubMed     Abstract available
    
    
    
74. SOCRATES AJ, Mullins N, Gur RC, Gur RE, et al
    Polygenic risk of social isolation behavior and its influence on psychopathology and personality.
    Mol Psychiatry. 2024;29:3599-3606.
    PubMed     Abstract available
    
    
    
75. LUO J, Li L, Niu M, Kong D, et al
    Genetic regulation of human brain proteome reveals proteins implicated in psychiatric disorders.
    Mol Psychiatry. 2024;29:3330-3343.
    PubMed     Abstract available
    
    
    October 2024
76. LEE H, Lee JH, Lee S, Lim JS, et al
    Comorbid health outcomes in patients with schizophrenia: an umbrella review of systematic reviews and meta-analyses.
    Mol Psychiatry. 2024 Oct 18. doi: 10.1038/s41380-024-02792.
    PubMed     Abstract available
    
    
    
77. DEVINE EA, Imami AS, Eby H, Sahay S, et al
    Neuronal alterations in AKT isotype expression in schizophrenia.
    Mol Psychiatry. 2024 Oct 18. doi: 10.1038/s41380-024-02770.
    PubMed     Abstract available
    
    
    
78. SCOTT DS, Subramanian M, Yamamoto J, Tamminga CA, et al
    Schizophrenia pathology reverse-translated into mouse shows hippocampal hyperactivity, psychosis behaviors and hyper-synchronous events.
    Mol Psychiatry. 2024 Oct 16. doi: 10.1038/s41380-024-02781.
    PubMed     Abstract available
    
    
    
79. DEMPSTER EL, Wong CCY, Burrage J, Hannon E, et al
    Methylomic signature of current cannabis use in two first-episode psychosis cohorts.
    Mol Psychiatry. 2024 Oct 16. doi: 10.1038/s41380-024-02689.
    PubMed     Abstract available
    
    
    
80. KEANE BP, Abrham YT, Cole MW, Johnson BA, et al
    Functional dysconnectivity of visual and somatomotor networks yields a simple and robust biomarker for psychosis.
    Mol Psychiatry. 2024 Oct 4. doi: 10.1038/s41380-024-02767.
    PubMed     Abstract available
    
    
    
81. LIUFU C, Luo L, Pang T, Zheng H, et al
    Integration of multi-omics summary data reveals the role of N6-methyladenosine in neuropsychiatric disorders.
    Mol Psychiatry. 2024;29:3141-3150.
    PubMed     Abstract available
    
    
    September 2024
82. CHOE E, Kim M, Choi S, Oh H, et al
    MRI textural plasticity in limbic gray matter associated with clinical response to electroconvulsive therapy for psychosis.
    Mol Psychiatry. 2024 Sep 26. doi: 10.1038/s41380-024-02755.
    PubMed     Abstract available
    
    
    
83. SAPIENZA J, Martini F, Comai S, Cavallaro R, et al
    Psychedelics and schizophrenia: a double-edged sword.
    Mol Psychiatry. 2024 Sep 18. doi: 10.1038/s41380-024-02743.
    PubMed     Abstract available
    
    
    
84. KILTSCHEWSKIJ DJ, Reay WR, Cairns MJ
    Schizophrenia is associated with altered DNA methylation variance.
    Mol Psychiatry. 2024 Sep 13. doi: 10.1038/s41380-024-02749.
    PubMed     Abstract available
    
    
    
85. GARCIA-SAN-MARTIN N, Bethlehem RAI, Mihalik A, Seidlitz J, et al
    Molecular and micro-architectural mapping of gray matter alterations in psychosis.
    Mol Psychiatry. 2024 Sep 12. doi: 10.1038/s41380-024-02724.
    PubMed     Abstract available
    
    
    
86. NANI JV, Muotri AR, Hayashi MAF
    Peering into the mind: unraveling schizophrenia's secrets using models.
    Mol Psychiatry. 2024 Sep 8. doi: 10.1038/s41380-024-02728.
    PubMed     Abstract available
    
    
    
87. ROMANOVSKY E, Choudhary A, Peles D, Abu-Akel A, et al
    Uncovering convergence and divergence between autism and schizophrenia using genomic tools and patients' neurons.
    Mol Psychiatry. 2024 Sep 5. doi: 10.1038/s41380-024-02740.
    PubMed     Abstract available
    
    
    
88. PHADKE RA, Brack A, Fournier LA, Kruzich E, et al
    The schizophrenia risk gene C4 induces pathological synaptic loss by impairing AMPAR trafficking.
    Mol Psychiatry. 2024 Sep 3. doi: 10.1038/s41380-024-02701.
    PubMed     Abstract available
    
    
    
89. CHAN JKN, Lee KCK, Correll CU, So YK, et al
    Adverse obstetric and neonatal outcomes associated with maternal schizophrenia-spectrum disorders and prenatal antipsychotic use: a meta-analysis of 37,214,330 pregnancy deliveries and propensity-score weighted population-based cohort study assessing
    Mol Psychiatry. 2024 Sep 2. doi: 10.1038/s41380-024-02723.
    PubMed     Abstract available
    
    
    
90. CROUSE JJ, Park SH, Byrne EM, Mitchell BL, et al
    Patterns of stressful life events and polygenic scores for five mental disorders and neuroticism among adults with depression.
    Mol Psychiatry. 2024;29:2765-2773.
    PubMed     Abstract available
    
    
    
91. GAITONDE SA, Avet C, de la Fuente Revenga M, Blondel-Tepaz E, et al
    Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT(2A) receptor.
    Mol Psychiatry. 2024;29:2753-2764.
    PubMed     Abstract available
    
    
    
92. KAMPE A, Suvisaari J, Lahteenvuo M, Singh T, et al
    Genetic contribution to disease-course severity and progression in the SUPER-Finland study, a cohort of 10,403 individuals with psychotic disorders.
    Mol Psychiatry. 2024;29:2733-2741.
    PubMed     Abstract available
    
    
    
93. GERACI F, Passiatore R, Penzel N, Laudani S, et al
    Sex dimorphism controls dysbindin-related cognitive dysfunctions in mice and humans with the contribution of COMT.
    Mol Psychiatry. 2024;29:2666-2677.
    PubMed     Abstract available
    
    
    August 2024
94. KAMBALI M, Li Y, Unichenko P, Feria Pliego JA, et al
    An increased copy number of glycine decarboxylase (GLDC) associated with psychosis reduces extracellular glycine and impairs NMDA receptor function.
    Mol Psychiatry. 2024 Aug 30. doi: 10.1038/s41380-024-02711.
    PubMed     Abstract available
    
    
    
95. AYMERICH C, Salazar de Pablo G, Pacho M, Perez-Rodriguez V, et al
    All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis.
    Mol Psychiatry. 2024 Aug 22. doi: 10.1038/s41380-024-02694.
    PubMed     Abstract available
    
    
    
96. LI Z, Mukherjee D, Duric B, Austin-Zimmerman I, et al
    Systematic review and meta-analysis on the effects of chronic peri-adolescent cannabinoid exposure on schizophrenia-like behaviour in rodents.
    Mol Psychiatry. 2024 Aug 2. doi: 10.1038/s41380-024-02668.
    PubMed     Abstract available
    
    
    
97. ALLOTT K, Chopra S, Rogers J, Dauvermann MR, et al
    Advancing understanding of the mechanisms of antipsychotic-associated cognitive impairment to minimise harm: a call to action.
    Mol Psychiatry. 2024;29:2571-2574.
    PubMed    
    
    
    July 2024
98. FORNARO M, Caiazza C, Billeci M, Berk M, et al
    Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis "Nutra NMA SCZ".
    Mol Psychiatry. 2024 Jul 18. doi: 10.1038/s41380-024-02645.
    PubMed     Abstract available
    
    
    
99. ARANDA S, Jimenez E, Canales-Rodriguez EJ, Verdolini N, et al
    Processing speed mediates the relationship between DDR1 and psychosocial functioning in euthymic patients with bipolar disorder presenting psychotic symptoms.
    Mol Psychiatry. 2024;29:2050-2058.
    PubMed     Abstract available
    
    
    June 2024
100. CAMPORESI S, Xin L, Golay P, Eap CB, et al
     Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study.
     Mol Psychiatry. 2024 Jun 7. doi: 10.1038/s41380-024-02631.
     PubMed     Abstract available
     
     
     
101. MARTINO M, Magioncalda P
     A working model of neural activity and phenomenal experience in psychosis.
     Mol Psychiatry. 2024 Jun 6. doi: 10.1038/s41380-024-02607.
     PubMed     Abstract available
     
     
     
102. CHO KIK, Zhang F, Penzel N, Seitz-Holland J, et al
     Excessive interstitial free-water in cortical gray matter preceding accelerated volume changes in individuals at clinical high risk for psychosis.
     Mol Psychiatry. 2024 Jun 3. doi: 10.1038/s41380-024-02597.
     PubMed     Abstract available
     
     
     
103. LIAO Y, Yu H, Zhang Y, Lu Z, et al
     Genome-wide association study implicates lipid pathway dysfunction in antipsychotic-induced weight gain: multi-ancestry validation.
     Mol Psychiatry. 2024;29:1857-1868.
     PubMed     Abstract available
     
     
     May 2024
104. STERN S, Zhang L, Wang M, Wright R, et al
     Monozygotic twins discordant for schizophrenia differ in maturation and synaptic transmission.
     Mol Psychiatry. 2024 May 4. doi: 10.1038/s41380-024-02561.
     PubMed     Abstract available
     
     
     
105. HILL MD, Gill SS, Le-Niculescu H, MacKie O, et al
     Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomics.
     Mol Psychiatry. 2024;29:1528-1549.
     PubMed     Abstract available
     
     
     
106. YANG K, Hasegawa Y, Bhattarai JP, Hua J, et al
     Inflammation-related pathology in the olfactory epithelium: its impact on the olfactory system in psychotic disorders.
     Mol Psychiatry. 2024;29:1453-1464.
     PubMed     Abstract available
     
     
     April 2024
107. SPATHOPOULOU A, Sauerwein GA, Marteau V, Podlesnic M, et al
     Integrative metabolomics-genomics analysis identifies key networks in a stem cell-based model of schizophrenia.
     Mol Psychiatry. 2024 Apr 29. doi: 10.1038/s41380-024-02568.
     PubMed     Abstract available
     
     
     
108. SHARKEY RJ, Bacon C, Peterson Z, Rootes-Murdy K, et al
     Differences in the neural correlates of schizophrenia with positive and negative formal thought disorder in patients with schizophrenia in the ENIGMA dataset.
     Mol Psychiatry. 2024 Apr 26. doi: 10.1038/s41380-024-02563.
     PubMed     Abstract available
     
     
     
109. SUPEKAR K, de Los Angeles C, Ryali S, Kushan L, et al
     Robust and replicable functional brain signatures of 22q11.2 deletion syndrome and associated psychosis: a deep neural network-based multi-cohort study.
     Mol Psychiatry. 2024 Apr 12. doi: 10.1038/s41380-024-02495.
     PubMed     Abstract available
     
     
     
110. TOTZEK JF, Chakravarty MM, Joober R, Malla A, et al
     Longitudinal inference of multiscale markers in psychosis: from hippocampal centrality to functional outcome.
     Mol Psychiatry. 2024 Apr 11. doi: 10.1038/s41380-024-02549.
     PubMed     Abstract available
     
     
     
111. OKADA N, Yahata N, Koshiyama D, Morita K, et al
     Longitudinal trajectories of anterior cingulate glutamate and subclinical psychotic experiences in early adolescence: the impact of bullying victimization.
     Mol Psychiatry. 2024;29:939-950.
     PubMed     Abstract available
     
     
     March 2024
112. CHEN S, Tan Y, Tian L
     Immunophenotypes in psychosis: is it a premature inflamm-aging disorder?
     Mol Psychiatry. 2024 Mar 26. doi: 10.1038/s41380-024-02539.
     PubMed     Abstract available
     
     
     
113. KOSKUVI M, Porsti E, Hewitt T, Rasanen N, et al
     Genetic contribution to microglial activation in schizophrenia.
     Mol Psychiatry. 2024 Mar 22. doi: 10.1038/s41380-024-02529.
     PubMed     Abstract available
     
     
     
114. TESFAYE M, Spindola LM, Stavrum AK, Shadrin A, et al
     Sex effects on DNA methylation affect discovery in epigenome-wide association study of schizophrenia.
     Mol Psychiatry. 2024 Mar 19. doi: 10.1038/s41380-024-02513.
     PubMed     Abstract available
     
     
     
115. FEOLA B, Beermann A, Manzanarez Felix K, Coleman M, et al
     Data-driven, connectome-wide analysis identifies psychosis-specific brain correlates of fear and anxiety.
     Mol Psychiatry. 2024 Mar 19. doi: 10.1038/s41380-024-02512.
     PubMed     Abstract available
     
     
     
116. BIGDELI TB, Barr PB, Rajeevan N, Graham DP, et al
     Correlates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder.
     Mol Psychiatry. 2024 Mar 15. doi: 10.1038/s41380-024-02472.
     PubMed     Abstract available
     
     
     
117. WARREN TL, Tubbs JD, Lesh TA, Corona MB, et al
     Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis.
     Mol Psychiatry. 2024 Mar 15. doi: 10.1038/s41380-024-02457.
     PubMed     Abstract available
     
     
     February 2024
118. FOUNTOULAKIS KN, Tsapakis EM
     Neither serotonin disorder is at the core of depression nor dopamine at the core of schizophrenia; still these are biologically based mental disorders.
     Mol Psychiatry. 2024 Feb 19. doi: 10.1038/s41380-024-02458.
     PubMed    
     
     
     
119. SONG J, Jonsson L, Lu Y, Bergen SE, et al
     Key subphenotypes of bipolar disorder are differentially associated with polygenic liabilities for bipolar disorder, schizophrenia, and major depressive disorder.
     Mol Psychiatry. 2024 Feb 14. doi: 10.1038/s41380-024-02448.
     PubMed     Abstract available
     
     
     
120. BENRIMOH D, Dlugunovych V, Wright AC, Phalen P, et al
     Correction: On the proportion of patients who experience a prodrome prior to psychosis onset: a systematic review and meta-analysis.
     Mol Psychiatry. 2024 Feb 14. doi: 10.1038/s41380-024-02481.
     PubMed    
     
     
     
121. KOTOV R, Carpenter WT, Cicero DC, Correll CU, et al
     Psychosis superspectrum II: neurobiology, treatment, and implications.
     Mol Psychiatry. 2024 Feb 14. doi: 10.1038/s41380-024-02410.
     PubMed     Abstract available
     
     
     
122. ZHU Y, Maikusa N, Radua J, Samann PG, et al
     Using brain structural neuroimaging measures to predict psychosis onset for individuals at clinical high-risk.
     Mol Psychiatry. 2024 Feb 9. doi: 10.1038/s41380-024-02426.
     PubMed     Abstract available
     
     
     
123. GEORGIADIS F, Lariviere S, Glahn D, Hong LE, et al
     Connectome architecture shapes large-scale cortical alterations in schizophrenia: a worldwide ENIGMA study.
     Mol Psychiatry. 2024 Feb 9. doi: 10.1038/s41380-024-02442.
     PubMed     Abstract available
     
     
     
124. BENRIMOH D, Dlugunovych V, Wright AC, Phalen P, et al
     On the proportion of patients who experience a prodrome prior to psychosis onset: A systematic review and meta-analysis.
     Mol Psychiatry. 2024 Feb 2. doi: 10.1038/s41380-024-02415.
     PubMed     Abstract available
     
     
     
125. PODVIN S, Jones J, Kang A, Goodman R, et al
     Human iN neuronal model of schizophrenia displays dysregulation of chromogranin B and related neuropeptide transmitter signatures.
     Mol Psychiatry. 2024 Feb 2. doi: 10.1038/s41380-024-02422.
     PubMed     Abstract available
     
     
     
126. SHAKESHAFT A, Martin J, Dennison CA, Riglin L, et al
     Estimating the impact of transmitted and non-transmitted psychiatric and neurodevelopmental polygenic scores on youth emotional problems.
     Mol Psychiatry. 2024;29:238-246.
     PubMed     Abstract available
     
     
     January 2024
127. CHUNG Y, Dienel SJ, Belch MJ, Fish KN, et al
     Altered Rbfox1-Vamp1 pathway and prefrontal cortical dysfunction in schizophrenia.
     Mol Psychiatry. 2024 Jan 25. doi: 10.1038/s41380-024-02417.
     PubMed     Abstract available
     
     
     
128. CHEN H, Lei Y, Li R, Xia X, et al
     Resting-state EEG dynamic functional connectivity distinguishes non-psychotic major depression, psychotic major depression and schizophrenia.
     Mol Psychiatry. 2024 Jan 24. doi: 10.1038/s41380-023-02395.
     PubMed     Abstract available
     
     
     
129. DAVIES C, Martins D, Dipasquale O, McCutcheon RA, et al
     Connectome dysfunction in patients at clinical high risk for psychosis and modulation by oxytocin.
     Mol Psychiatry. 2024 Jan 19. doi: 10.1038/s41380-024-02406.
     PubMed     Abstract available
     
     
     
130. WOLFF A, Northoff G
     Temporal imprecision of phase coherence in schizophrenia and psychosis-dynamic mechanisms and diagnostic marker.
     Mol Psychiatry. 2024 Jan 16. doi: 10.1038/s41380-023-02337.
     PubMed     Abstract available
     
     
     
131. JONAS KG, Cannon TD, Docherty AR, Dwyer D, et al
     Psychosis superspectrum I: Nosology, etiology, and lifespan development.
     Mol Psychiatry. 2024 Jan 10. doi: 10.1038/s41380-023-02388.
     PubMed     Abstract available
     
     
     
132. SI S, Bi A, Yu Z, See C, et al
     Mapping gray and white matter volume abnormalities in early-onset psychosis: an ENIGMA multicenter voxel-based morphometry study.
     Mol Psychiatry. 2024 Jan 10. doi: 10.1038/s41380-023-02343.
     PubMed     Abstract available
     
     
     
133. RUBIO JM, Lencz T, Cao H, Kraguljac N, et al
     Replication of a neuroimaging biomarker for striatal dysfunction in psychosis.
     Mol Psychiatry. 2024 Jan 4. doi: 10.1038/s41380-023-02381.
     PubMed     Abstract available
     
     
     December 2023
134. DONG P, Voloudakis G, Fullard JF, Hoffman GE, et al
     Convergence of the dysregulated regulome in schizophrenia with polygenic risk and evolutionarily constrained enhancers.
     Mol Psychiatry. 2023 Dec 25. doi: 10.1038/s41380-023-02370.
     PubMed     Abstract available
     
     
     
135. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
     The relationship between familial-genetic risk and pharmacological treatment in a Swedish national sample of patients with major depression, bipolar disorder, and schizophrenia.
     Mol Psychiatry. 2023 Dec 20. doi: 10.1038/s41380-023-02365.
     PubMed     Abstract available
     
     
     
136. KOMATSU H, Onoguchi G, Silverstein SM, Jerotic S, et al
     Retina as a potential biomarker in schizophrenia spectrum disorders: a systematic review and meta-analysis of optical coherence tomography and electroretinography.
     Mol Psychiatry. 2023 Dec 11. doi: 10.1038/s41380-023-02340.
     PubMed     Abstract available
     
     
     
137. OKADA N, Fukunaga M, Miura K, Nemoto K, et al
     Subcortical volumetric alterations in four major psychiatric disorders: a mega-analysis study of 5604 subjects and a volumetric data-driven approach for classification.
     Mol Psychiatry. 2023;28:5206-5216.
     PubMed     Abstract available
     
     
     
138. GRIECO SF, Johnston KG, Gao P, Garduno BM, et al
     Anatomical and molecular characterization of parvalbumin-cholecystokinin co-expressing inhibitory interneurons: implications for neuropsychiatric conditions.
     Mol Psychiatry. 2023;28:5293-5308.
     PubMed     Abstract available
     
     
     
139. WEI W, Deng L, Qiao C, Yin Y, et al
     Neural variability in three major psychiatric disorders.
     Mol Psychiatry. 2023;28:5217-5227.
     PubMed     Abstract available
     
     
     
140. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
     Selecting cases of major psychiatric and substance use disorders in Swedish national registries on the basis of clinical features to maximize the strength or specificity of the genetic risk.
     Mol Psychiatry. 2023;28:5195-5205.
     PubMed     Abstract available
     
     
     
141. ZHENG H, Webster MJ, Weickert CS, Beasley CL, et al
     Cytomegalovirus antibodies are associated with mood disorders, suicide, markers of neuroinflammation, and microglia activation in postmortem brain samples.
     Mol Psychiatry. 2023;28:5282-5292.
     PubMed     Abstract available
     
     
     November 2023
142. NORTHOFF G, Daub J, Hirjak D
     Overcoming the translational crisis of contemporary psychiatry - converging phenomenological and spatiotemporal psychopathology.
     Mol Psychiatry. 2023;28:4492-4499.
     PubMed     Abstract available
     
     
     October 2023
143. OWEN MJ, Legge SE, Rees E, Walters JTR, et al
     Genomic findings in schizophrenia and their implications.
     Mol Psychiatry. 2023 Oct 18. doi: 10.1038/s41380-023-02293.
     PubMed     Abstract available
     
     
     
144. LESH TA, Iosif AM, Tanase C, Vlasova RM, et al
     Extracellular free water elevations are associated with brain volume and maternal cytokine response in a longitudinal nonhuman primate maternal immune activation model.
     Mol Psychiatry. 2023;28:4185-4194.
     PubMed     Abstract available
     
     
     
145. ARNATKEVICIUTE A, Lemire M, Morrison C, Mooney M, et al
     Trans-ancestry meta-analysis of genome wide association studies of inhibitory control.
     Mol Psychiatry. 2023;28:4175-4184.
     PubMed     Abstract available
     
     
     
146. RAVEN EP, Veraart J, Kievit RA, Genc S, et al
     In vivo evidence of microstructural hypo-connectivity of brain white matter in 22q11.2 deletion syndrome.
     Mol Psychiatry. 2023;28:4342-4352.
     PubMed     Abstract available
     
     
     September 2023
147. ODKHUU S, Kim WS, Tsogt U, Shen J, et al
     Network biomarkers in recovered psychosis patients who discontinued antipsychotics.
     Mol Psychiatry. 2023 Sep 29. doi: 10.1038/s41380-023-02279.
     PubMed     Abstract available
     
     
     
148. HARRISON PJ, Bannerman DM
     GRIN2A (NR2A): a gene contributing to glutamatergic involvement in schizophrenia.
     Mol Psychiatry. 2023 Sep 22. doi: 10.1038/s41380-023-02265.
     PubMed     Abstract available
     
     
     
149. ZHOU J, Xia Y, Li M, Chen Y, et al
     A higher dysregulation burden of brain DNA methylation in female patients implicated in the sex bias of Schizophrenia.
     Mol Psychiatry. 2023 Sep 11. doi: 10.1038/s41380-023-02243.
     PubMed     Abstract available
     
     
     
150. FLYNN LT, Gao WJ
     DNA methylation and the opposing NMDAR dysfunction in schizophrenia and major depression disorders: a converging model for the therapeutic effects of psychedelic compounds in the treatment of psychiatric illness.
     Mol Psychiatry. 2023 Sep 7. doi: 10.1038/s41380-023-02235.
     PubMed     Abstract available
     
     
     
151. SOLMI M, Cortese S, Vita G, De Prisco M, et al
     An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders.
     Mol Psychiatry. 2023;28:3671-3687.
     PubMed     Abstract available
     
     
     
152. MERRITT K, Luque Laguna P, Sethi A, Drakesmith M, et al
     The impact of cumulative obstetric complications and childhood trauma on brain volume in young people with psychotic experiences.
     Mol Psychiatry. 2023;28:3688-3697.
     PubMed     Abstract available
     
     
     
153. WOOTTON O, Shadrin AA, Mohn C, Susser E, et al
     Genome-wide association study in 404,302 individuals identifies 7 significant loci for reaction time variability.
     Mol Psychiatry. 2023;28:4011-4019.
     PubMed     Abstract available
     
     
     
154. CAMPBELL PD, Lee I, Thyme S, Granato M, et al
     Mitochondrial proteins encoded by the 22q11.2 neurodevelopmental locus regulate neural stem and progenitor cell proliferation.
     Mol Psychiatry. 2023;28:3769-3781.
     PubMed     Abstract available
     
     
     August 2023
155. NURMI EL, Laughlin CP, de Wit H, Palmer AA, et al
     Polygenic contributions to performance on the Balloon Analogue Risk Task.
     Mol Psychiatry. 2023;28:3524-3530.
     PubMed     Abstract available
     
     
     
156. HETTEMA JM, van den Oord EJCG, Zhao M, Xie LY, et al
     Methylome-wide association study of anxiety disorders.
     Mol Psychiatry. 2023;28:3484-3492.
     PubMed     Abstract available
     
     
     May 2023
157. LICINIO J, Wong ML
     Psychosis and autism spectrum disorder: a special issue of Molecular Psychiatry.
     Mol Psychiatry. 2023;28:1830-1832.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.